TECHNOLOGY TRENDS IN THE DEVELOPMENT AND COMMERCIALSCALE MANUFACTURING OF CELL AND GENE THERAPIES

doi:10.4066/2591-7951-C2-025

TECHNOLOGY TRENDS IN THE DEVELOPMENT AND COMMERCIALSCALE MANUFACTURING OF CELL AND GENE THERAPIES

Joint Event on 2^nd International Conference on CELL AND GENE THERAPY & 2^nd World Congress on PUBLIC HEALTH, EPIDEMIOLOGY AND NUTRITION
April 15-16, 2019 | Milan, Italy

Bryan Poltilove

Thermo Fisher Scientific, USA

Keynote : Arch Gen Intern Med

DOI: 10.4066/2591-7951-C2-025

Abstract:

The cell and gene therapy industry has now exceeded 1000 clinical trials and annual global financing increased 40% YOY to over $10B (ARM 2018 Q3 Report). As the industry continues its monumental expansion, developers much find new methods to scale their supply chains to control costs, speed and reproducibility. Meanwhile new regulations and standards are increasing pressure for more controlled processes, validation and risk mitigation. Raw material documentation, supply chain redundancy and closed manufacturing systems are key aspects to enabling the next wave of therapies. This talk will showcase some of the latest trends in the industry, emerging technologies and best practices that start early in development to enable robust, sustainable operations and commercial success.

Biography:

Bryan Poltilove is general manager of cell and gene therapy, he has overall P&L responsibility for the Thermo Fisher business segment, including long-range product line strategy, investment and day-to-day business operations. Previously, he led a $350M business segment of cell biology reagents and instrumentation. Prior to joining Thermo Fisher, he served as the Director of Revenue Strategy and Operations for the Corporate Executive Board and held several roles with Johnson & Johnson. He holds Bachelor degrees in Chemical Engineering and Economics from MIT and an MBA from Northwestern University, USA.

E-mail: bryan.poltilove@thermofisher.com

PDF HTML